MEDANTA (Global Health) Share Price in 2025: Chart, Monthly Trends, & Analysis
Advertisement
MEDANTA (Global Health)Share Price HistoryTomorrow TargetLong Term TargetNo DividendsNo BonusNo Split
How did MEDANTA (Global Health) shares perform in 2025?
Let's find out!
MEDANTA (Global Health) share price in 2025 was ₹1,089.09 Its price on 1st January 2025 was ₹1,081.59, and by 31st December 2025 it moved to ₹1,089.09, giving a positive return of 0.69% for the year.
MEDANTA (Global Health) Share Open, High, Low, and Close prices for the Year 2025 are as follows:
Open | High | Low | Close |
---|---|---|---|
₹1,081.59 | ₹1,115.2 | ₹1,078.5 | ₹1,089.09 |
1st Jan 2025 | Occured in Jan 2025 | Occured in Jan 2025 | 31st Dec 2025 |
This page will help you understand how MEDANTA (Global Health) performed in 2025. Let's get started.
For complete insights into MEDANTA (Global Health)’s incredible stock price performance and growth, see: MEDANTA (Global Health) Historical Share Price Data from its IPO to 2025
Table: MEDANTA (Global Health) Share Monthly Close, Low, High Prices for 2025
Advertisement
Month | MEDANTA (Global Health) | Change% | ↑High - ↓Low |
---|---|---|---|
Jan | ₹1,089.09 | - | ↑ ₹1,115.2 ↓ ₹1,078.5 |
Chart: CandleStick and Line Chart Showing Monthly Prices
[Click on line name to show/hide a line]
What if You invested ₹10,000 in MEDANTA (Global Health) in 2025?
In 2025, the opening price of MEDANTA (Global Health) share was ₹1081.60. Today, the price stands at ₹1,089.09, reflecting a growth of 0.69%. If we applying the same growth to your investment of ₹10,000 then, your investment of ₹10,000 in 2025 would have become ₹10,069.34 by 2025. This represents a CAGR of 0.69%.
You might also like to check: MEDANTA (Global Health) Stock Price in 2024
References:
Stock prices on stockpricearchive.com are gathered from reliable sources only. We take prices from stock exchanges only, majorly from BSE and NSE.
Disclaimer: Information is provided ‘as is’ and solely for informational purposes, not for trading purposes or advice.